<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03876262</url>
  </required_header>
  <id_info>
    <org_study_id>MDGH-MOX-3001</org_study_id>
    <nct_id>NCT03876262</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Onchocerciasis</brief_title>
  <official_title>A Randomized, Double Blind, Parallel Trial in the Democratic Republic of Congo (DRC) Comparing the Safety and Efficacy of Annual or Biannual Doses of Moxidectin or Ivermectin for Treatment of Onchocerciasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medicines Development for Global Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medicines Development for Global Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this phase 3b study is to determine the safety and efficacy of&#xD;
      moxidectin administration twice a year, compared to once a year, in maintaining undetectable&#xD;
      levels in skin of O. volvulus microfilaria in skin, the parasite that causes river blindness.&#xD;
&#xD;
      Secondary purposes are to determine the effectiveness of moxidectin compared to ivermectin&#xD;
      once or twice a year in maintaining undetectable levels, or reducing levels, of skin&#xD;
      microfilaria.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2021</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Participants will be assigned to four groups: annual ivermectin; annual moxidectin; biannual ivermectin; or biannual moxidectin</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of moxidectin annual and biannual recipients with sustained microfilarial response at month 12</measure>
    <time_frame>Up to 12 months</time_frame>
    <description>Proportion of recipients with zero Onchocerca volvulus microfilariae/mg skin at all post-treatment timepoints to month 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and severity of adverse events</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>Incidence and severity of adverse events, vital signs and liver function tests</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Proportion of participants in all dose groups with sustained microfilariae response</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months, 30 months, 36 months</time_frame>
    <description>Proportion of participants with zero Onchocerca volvulus microfilariae/mg skin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sustained ocular microfilariae response in all dose groups</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months, 30 months, 36 months</time_frame>
    <description>Proportion of participants with 0 live O. volvulus microfilariae in the anterior chambers of the eyes at all post-Baseline assessments in those with liver ocular microfilariae before the first treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Skin microfilarial density in all dose groups</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months, 30 months, 36 months</time_frame>
    <description>Mean, median and percentage reduction Onchocerca volvulus microfilariae/mg skin from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular microfilariae response in all dose groups</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months, 30 months, 36 months</time_frame>
    <description>Proportion of participants in all dose groups with 0 Onchocerca volvulus microfilariae/mg skin and 0 live microfilariae in the anterior chambers of the eyes each timepoint</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean skin microfilariae density at each post-Screening assessment</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months, 30 months, 36 months</time_frame>
    <description>Mean and mean change from baseline of Onchocerca volvulus microfilariae/mg skin</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Signs and symptoms of onchocerciasis in all dose groups</measure>
    <time_frame>6 months, 12 months, 18 months, 24 months, 30 months, 36 months</time_frame>
    <description>Proportion of participants with signs and symptoms of onchocerciasis with these signs and symptoms at baseline.</description>
  </other_outcome>
  <other_outcome>
    <measure>Viability and fertility of male and female macrofilariae in all dose groups</measure>
    <time_frame>36 months</time_frame>
    <description>Histopathological assessment of male and female macrofilariae excised from participants with palpable nodules</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1000</enrollment>
  <condition>Onchocerciasis</condition>
  <arm_group>
    <arm_group_label>Annual Moxidectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxidectin 8mg per oral, administered annually for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biannual Moxidectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Moxidectin 8mg per oral, administered biannually for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Annual Ivermectin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ivermectin (approximately) 150 micrograms/kg per oral, administered annually for 24 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Biannual Ivermectin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ivermectin (approximately) 150 micrograms/kg per oral, administered biannually for 24 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moxidectin</intervention_name>
    <description>2mg tablets, encapsulated for blinding</description>
    <arm_group_label>Annual Moxidectin</arm_group_label>
    <arm_group_label>Biannual Moxidectin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin</intervention_name>
    <description>3mg tablets, encapsulated for blinding</description>
    <arm_group_label>Annual Ivermectin</arm_group_label>
    <arm_group_label>Biannual Ivermectin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Provision of written informed consent, or assent with parental or guardian written&#xD;
             consent.&#xD;
&#xD;
          -  Mean ≥ 10 O. volvulus microfilariae/mg skin, determined by four skin snips&#xD;
&#xD;
          -  Living in a village selected for the study.&#xD;
&#xD;
          -  Age ≥ 12 years.&#xD;
&#xD;
          -  All female participants of childbearing potential must commit to the use of a reliable&#xD;
             method of birth control for the duration of treatment and until 3 months after&#xD;
             completion of dosing with investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or breast-feeding.&#xD;
&#xD;
          -  Any concurrent condition that, in the opinion of the Investigator, would preclude&#xD;
             evaluation of response to treatment or would pose undue risk to the participant's&#xD;
             health.&#xD;
&#xD;
          -  Has received ivermectin, oral diethylcarbamazine (DEC) or doxycycline (for &gt; 2 weeks)&#xD;
             within 6 months of Baseline.&#xD;
&#xD;
          -  Has received treatment with an investigational agent within the last 30 days (or 5&#xD;
             half-lives, whichever is longer) prior to Baseline.&#xD;
&#xD;
          -  Known or suspected allergy to ivermectin or moxidectin or their excipients.&#xD;
&#xD;
          -  Self-reported planned or ongoing activities within the study period that would make it&#xD;
             unlikely that a participant will be available for all planned treatment rounds and&#xD;
             follow-up examinations.&#xD;
&#xD;
          -  Weight &gt; 88 kg.&#xD;
&#xD;
          -  Infection with Loa loa.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tony Ukety, MD, DO, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre de Recherche en Maladies Tropicales de l'Ituri</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sally Kinrade</last_name>
    <phone>+61 3 9912 2400</phone>
    <email>sally.kinrade@medicinesdevelopment.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Beatriz Mosqueira</last_name>
    <phone>+61 3 9912 2400</phone>
    <email>beatriz.mosqueira@medicinesdevelopment.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Centre de Recherche pour les Maladies Tropicales Negligees</name>
      <address>
        <city>Rethy</city>
        <state>Ituri</state>
        <country>Congo, The Democratic Republic of the</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Tony Ukety</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Congo, The Democratic Republic of the</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 11, 2019</study_first_submitted>
  <study_first_submitted_qc>March 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2019</study_first_posted>
  <last_update_submitted>September 29, 2021</last_update_submitted>
  <last_update_submitted_qc>September 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onchocerciasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
    <mesh_term>Moxidectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 30, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/62/NCT03876262/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

